Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech Reports Sales Growth; Remains Hopeful About Avastin Approval For Breast Cancer

This article was originally published in The Pink Sheet Daily

Executive Summary

While its pipeline largely consists of line extensions, firm touts 15 novel compounds added during 2006-2007.

You may also be interested in...

In Narrow Vote, ODAC Votes Against Avastin In Breast Cancer

Oncologic Drugs Advisory Committee expresses concerns about overall survival, toxicity and study conduct.

Genentech Product Sales Rise 18 Percent, Led By Avastin, Though Lucentis A Disappointment

Firm would bid on remaining rights to Rituxan should a change of control occur at Biogen Idec, CFO Ebersman says during third quarter call .

Novartis Faces Another Challenge To Entresto In India

More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts